Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: The 'OPTIMIZE-IT' pilot randomized study

Francesco Burzotta, Carlo Trani, Felicita Andreotti, Filippo Crea, Italo Porto, Maria De Vita, Antonio Maria Leone, Giampaolo Niccoli, Mario Attilio Mazzari, Giovanni Schiavoni

Risultato della ricerca: Contributo in rivistaArticolo in rivista

19 Citazioni (Scopus)

Abstract

BACKGROUND: Subgroup analyses of trials enrolling acute coronary syndrome patients suggest that inhibition of glycoprotein IIb/IIIa can improve the outcome of diabetic patients undergoing percutaneous coronary interventions (PCIs), possibly by improving microvascular perfusion. However, the efficacy of small-molecule IIb/IIIa receptor inhibitors to improve microvascular perfusion in stable diabetic patients undergoing elective PCI has not been specifically investigated. METHODS: We randomized consecutive stable diabetic patients, undergoing elective PCI, to tirofiban or placebo groups along with double antiplatelet therapy. High-dose bolus (25 μg/kg per 3 min) of tirofiban was administered immediately before PCI followed by 8 h continuous infusion (0.15 μg/kg per min). Postprocedural myonecrosis was assessed prospectively by measurement of cardiac troponin T (cTnT) at 6 and 24 h after PCI. The primary end-points were post-PCI coronary flow estimated by corrected thrombolysis in myocardial infarction frame count and post-PCI myocardial infarction. Platelet aggregation was measured by platelet function analyser-100 values. RESULTS: Forty-six patients entered the study (22 randomized to placebo and 24 randomized to tirofiban). The study drug was associated with a significant increase of platelet function analyser-100 values that peaked immediately after PCI and was maintained at 6 h (pre-PCI: 131 ± 65 s; post-PCI: 222 ± 49 s; after 6 h: 219 ± 55 s).Post-PCI corrected thrombolysis in myocardial infarction frame count was similar in tirofiban and in placebo groups (10.2 ± 3.6 vs. 12.0 ± 7.6, P = 0.30, respectively). The prevalence of raised cTnT levels was similar in the two groups (25 vs. 30%, P = 0.56, respectively). At multivariate analysis, direct stenting (associated with reduced myonecrosis) and postdilatation (associated with increased myonecrosis) predicted cTnT elevation. CONCLUSION: A high-dose bolus of tirofiban in stable diabetic patients undergoing elective PCI, along with double antiplatelet therapy, was associated with a significant further inhibition of platelet aggregation which, however, did not translate in a lower incidence of post-PCI distal embolization. © 2009 Italian Federation of Cardiology.
Lingua originaleEnglish
pagine (da-a)245-251
Numero di pagine7
RivistaJournal of Cardiovascular Medicine
Volume10
DOI
Stato di pubblicazionePubblicato - 2009

Keywords

  • Diabetes mellitus
  • IIb/IIIa inhibitors
  • Percutaneous coronary interventions

Fingerprint Entra nei temi di ricerca di 'Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: The 'OPTIMIZE-IT' pilot randomized study'. Insieme formano una fingerprint unica.

Cita questo